Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Sanofi Winthrop Industrie

< Previous 1 2 Next >
News headline image
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Availability of the Q4 2025 Aide memoire
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi completes acquisition of Vicebio
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Sanofi successfully prices USD 3 billion of bond issue
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Q3: continued sales and earnings progress
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Availability of the Q3 2025 Aide mémoire
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.